Jan 29, 2009 - Betagenon announced that its lead AMPK activator drug candidate BG8702 aimed for the treatment of type2 diabetes has started Investigational Medicinal Product enabling studies in the UK. The selected compound is derived from the in-house drug discovery AMPK activator program. Treatment with BG8702 leads to significant improvement of insulin sensitivity, glucose and triglyceride lowering in diabetic mouse models... Betagenon's Press Releases -
Wednesday, January 13, 2010
Betagenon : its lead AMPK activator drug candidate BG8702 has started IMP enabling studies in the UK
Jan 29, 2009 - Betagenon announced that its lead AMPK activator drug candidate BG8702 aimed for the treatment of type2 diabetes has started Investigational Medicinal Product enabling studies in the UK. The selected compound is derived from the in-house drug discovery AMPK activator program. Treatment with BG8702 leads to significant improvement of insulin sensitivity, glucose and triglyceride lowering in diabetic mouse models... Betagenon's Press Releases -
Monday, December 21, 2009
Array and Amgen : Partner in Type 2 Diabetes
Dec 14, 2009 - Amgen to Pay $60 Million Up-front with Additional Potential Milestones and Royalties - Array BioPharma Inc. (NASDAQ: ARRY) and Amgen Inc.(NASDAQ: AMGN) announced that they entered into an agreement granting Amgen exclusive worldwide rights to Array's small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes.
Under the terms of the agreement, Array will receive an upfront payment of $60 million and additional contingent payments for certain clinical and commercial milestones. Array is responsible for completing the Phase 1 trial for ARRY-403. Amgen is responsible for future clinical development and commercialization for ARRY-403 and any resulting back-up compounds, with Array having an option to co-promote in the United States. Array will receive double digit royalties on sales of ARRY-403. In addition, Amgen will fund an agreed upon number of full-time Array employees as part of a two-year research collaboration intended to identify and advance second-generation glucokinase activators... Array BioPharma's Press Release - Amgen's Press Release -
Libellés :
Amgen,
Array BioPharma,
Type 2 Diabetes
Biocompatibles and AstraZeneca : Schedule of Phase I and Phase II Trials agreed for Type II Diabetes Drug
4 December 2009: Biocompatibles International plc is pleased to announce that it will initiate clinical trials for CM3, a type II diabetes drug, under development with AstraZeneca, in January. Biocompatibles entered into an agreement with AstraZeneca in December 2008 to develop CM3. The agreement included pre-clinical, Phase I and Phase IIa activities managed by Biocompatibles’ subsidiary, CellMed. Phase I studies are scheduled to start early in 2010 and Phase II studies are expected to start later in 2010. The pre-clinical phase of the programme was completed ahead of schedule with positive results.
A further €4.3m instalment of a schedule of payments of €8.8m, first announced by Biocompatibles on 22 December 2008, will be paid by AstraZeneca in January.
CM3 is a glucagon-like peptide-1 (GLP-1) analogue invented and developed by CellMed and is part of a new family of GLP-1 analogues. The first of the relevant patents has recently been granted. This GLP-1 compound has the potential to be an important treatment for diabetes and obesity and may offer patient benefits not currently available from other GLP-1 drugs on the market.
The agreement also provides AstraZeneca with an exclusive option to license relevant patents for further exploitation, at any time during the course of the development programme, which is expected to be completed in 2012... Biocompatibles' Press Release -
Libellés :
AstraZeneca,
Biocompatibles,
Type 2 Diabetes
Monday, November 23, 2009
GI Dynamics' EndoBarrierTM Gastrointestinal Liner : Significant HbA1c Reduction in Obese People Living with Type 2 Diabetes
“Studies show that every one percent decrease in HbA1c reduces health risks by 21 percent and as the rates of obesity and type 2 diabetes continue to reach epidemic proportions around the globe, patients are in urgent need of new therapeutic solutions that overcome the limitations associated with pharmaceutical regimens and invasive surgery,... GI Dynamics' Press Release -
First Diabetes Patient Adherence Program for Foot Ulcer Treatment
November 3, 2009 – Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine and the maker of Dermagraft®, launched during American Diabetes Month the Heal2gether Partnership Program for diabetes patients and their physicians. Focused on patient adherence, Heal2gether aims to increase awareness and proper care of diabetic foot ulcers (DFUs), enhance the effective use of living cell technologies in treating DFUs, and encourage patients to take an active role in their healing process... Advanced BioHealing's Press Release -
Wednesday, November 11, 2009
Compugen : Discovery of Genetic Biomarker for Predisposition to Type 2 Diabetes
November 9, 2009 - Compugen Ltd. (NASDAQ: CGEN) announced the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes, the most common form of diabetes. This new biomarker was discovered using Compugen’s GeneVa® platform, which consists of an in silico database of approximately 350,000 predicted genetic variations in the human genome, with each predicted variation consisting of multiple consecutive nucleotides.Predisposition markers are of particular value in diseases like type 2 diabetes, where specific lifestyle and health factors are known to play an important role. Following diagnosis, high-risk patients may benefit from more aggressive management either through lifestyle modification or drug treatment. There are an estimated 24 million people in the U.S. with diabetes, 90% of whom are affected by type 2 diabetes.During the past few years, extensive efforts by others searching for genetic markers for type 2 diabetes have utilized numerous genome-wide association studies, involving thousands of patients globally. Several validated genetic markers have been found; however, combining all the discovered biomarkers still explains only a small fraction of the heritability of the disease, so the need for additional markers continues to exist... Compugen's Press Release -
Ossulin, a Novel Oral Insulin : Promising Bioavailability for Advancing Diabetes Therapy
9th November 2009 - New data from Puredel Limited, presented at the 9th Annual Diabetes Technology Meeting in San Francisco, California, suggest that higher blood levels of insulin were achieved by Ossulin than had been prevously demonstrated by other products. In a series of experiements in a range of doses and models, Ossulin consistently delivered around 20% of the insulin dose into the bloodstream.The authors concluded that:
'Ossulin provides an efficient way to deliver insulin to the body by oral administration, resulting in blood levels higher than those previously observed with other oral insulin products.'... CM&D Pharma' Press Release -
Thursday, November 5, 2009
CPEX’s Nasulin Insulin Therapy Featured in an Oral Presentation and Four Abstracts at the Ninth Annual Diabetes Technology Meeting
November 05, 2009 -CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) announced that its intranasal insulin product candidate, NasulinTM, will be featured in an oral presentation and four abstracts at the Ninth Annual Diabetes Technology Meeting, November 5-7, 2009 at the Hyatt Regency Airport in San Francisco, California. Dr. Lance Berman, Senior Vice President and Chief Medical Officer, is scheduled to deliver an oral presentation entitled “The Technology and Clinical Aspects of Nasal Insulin Therapy” at 9:30 a.m. PST on Saturday, November 7. Further details on the abstracts are provided below.A Randomized 6-Way Crossover Study of NasulinTM, Saline and Lispro in Subjects with Type 2 Diabetes to Determine Optimum Dose Timing
A similar glucose-lowering effect may be achieved by administering Nasulin either just before or at the end of the meal offering more flexibility of dosing than with injectable insulins.
Two Randomized Crossover Glucose Clamp Studies of NasulinTM and Lispro
In both Type1 diabetic patients and healthy volunteers, peak glucose metabolism rates occurred earlier with ultra-rapid acting Nasulin than with rapid acting lispro. The pharmacodynamic profile indicates Nasulin has optimum activity when glucose levels rise during a meal with less potential for hypoglycemia in the hours after the meal has ended.
Dose-Exposure for Single and Dual Nostril Administration of Nasal Insulin (NasulinTM)
The findings from this study demonstrated significantly enhanced insulin absorption when a 50 IU dose is administered as 2 sprays of 25 IU given in the same nostril rather than one spray in each nostril. In addition, the study also demonstrated that nasal administration of up to 200 microliters per nostril was well tolerated allowing the administration of doses up to 100 IU. Together these findings provide an improved dosing methodology and a higher maximum dose for evaluation in future clinical trials.
Dose-Exposure for Two Dose Strengths of Nasal Insulin (NasulinTM)
These data demonstrated that the original Nasulin concentration (1.0%) and the new concentration (0.7%) revealed proportional dose-dependent increases in insulin exposures... [PDF] CPEX Pharmaceuticals' Press Release -
Libellés :
CPEX Pharmaceuticals,
Insulin,
Type 1 Diabetes
Sunday, October 25, 2009
GlycoMimetics : Awarded NIH Grant to Study Drug Candidate in Diabetes
August 16, 2009 -- GlycoMimetics, Inc., a clinical-stage biotechnology company that is developing a new class of glycobiology-based therapies for a broad range of indications, announced it has been awarded a grant from The National Heart, Lung, and Blood Institute (NHLBI) of The National Institutes of Health (NIH) to evaluate its E-selectin small molecule antagonists in animal models of vascular complications of diabetes.The grant is based upon substantial data in the scientific literature suggesting an important role for E-selectin in the chronic inflammation associated with diabetes. The company has developed a family of potent small molecule E-selectin antagonists which it is currently optimizing for oral availability... GlycoMimetics' Press Release -
EXSULIN : PUBLICATION OF PHASE 2 TRIAL RESULTS FOR NOVEL ISLET REGENERATION TREATMENT IN TYPE 1 & TYPE 2 DIABETES
(August 18, 2009) – Exsulin Corporation announced milestones achieved and immediate plans to move forward as a well supported Minnesota-based company dedicated to the development of regeneration therapies for the treatment of diabetes mellitus. Exsulin’s focus is on development of a drug with potential to become a breakthrough therapy for patients suffering from type 1 (T1DM) and type 2 diabetes (T2DM). Phase II human clinical trial data of ExsulinTM (INGAP peptide), a peptide drug product aimed at restoring the ability of the pancreas to produce insulin normally in people with diabetes mellitus, have just been published online by Diabetes/Metabolism Research and Reviews.

Exsulin Corporation, founded by diabetes industry professionals, is supported by a proven clinical, development and regulatory management team and is advised by globally recognized diabetes experts. To follow on and support the results documented in the recent trial data publication, Exsulin has received clearances for a trial in patients with established (not newly diagnosed) T1DM, a population subset with no other currently active clinical trials. Other milestones achieved by Exsulin include reformulation and procurement of drug product, support of key independent laboratory research, and securing regulatory authorization to initiate a new clinical trial... Exsulin's Press Release -

Exsulin Corporation, founded by diabetes industry professionals, is supported by a proven clinical, development and regulatory management team and is advised by globally recognized diabetes experts. To follow on and support the results documented in the recent trial data publication, Exsulin has received clearances for a trial in patients with established (not newly diagnosed) T1DM, a population subset with no other currently active clinical trials. Other milestones achieved by Exsulin include reformulation and procurement of drug product, support of key independent laboratory research, and securing regulatory authorization to initiate a new clinical trial... Exsulin's Press Release -
Libellés :
Exsulin,
Type 1 Diabetes,
Type 2 Diabetes
Lexicon : Phase 1 Clinical Trial and Phase 2 Clinical Trial of LX4211 in Patients with Type 2 Diabetes
Libellés :
Lexicon Pharmaceuticals,
Type 2 Diabetes
Subscribe to:
Posts (Atom)